{"id":"standard-rfsh-dose","safety":{"commonSideEffects":[{"rate":"1-10%","effect":"Ovarian hyperstimulation syndrome (OHSS)"},{"rate":"5-15%","effect":"Headache"},{"rate":"5-10%","effect":"Injection site reactions"},{"rate":"10-20%","effect":"Abdominal pain/bloating"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-15%","effect":"Ovarian cysts"}]},"_chembl":{"chemblId":"CHEMBL261657","moleculeType":"Small molecule","molecularWeight":"405.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"rFSH is a recombinant version of the naturally occurring pituitary hormone FSH that binds to FSH receptors on granulosa cells in the ovary, promoting follicle development and estrogen production. This controlled stimulation is used during assisted reproductive technology cycles to generate multiple mature oocytes for retrieval and fertilization.","oneSentence":"Recombinant follicle-stimulating hormone (rFSH) stimulates the growth and maturation of ovarian follicles in women undergoing fertility treatment.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:23:28.421Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovulation induction in women with anovulation or oligo-ovulation"},{"name":"Controlled ovarian hyperstimulation in assisted reproductive technology (ART) cycles"},{"name":"In vitro fertilization (IVF)"}]},"trialDetails":[{"nctId":"NCT07108621","phase":"PHASE3","title":"hCG Priming in Women With Diminished Ovarian Reserve","status":"RECRUITING","sponsor":"Kristine Loessl","startDate":"2025-09","conditions":"Infertility, Female, Ovarian Reserve, In Vitro Fertilization (IVF)","enrollment":80},{"nctId":"NCT05864937","phase":"","title":"C677T Methylenetetrahydrofolate Reductase Mutation","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2011-12-01","conditions":"Mutation","enrollment":363},{"nctId":"NCT04643925","phase":"PHASE4","title":"hCG Priming in Women With Low Ovarian Reserve","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2020-12-27","conditions":"Infertility, Female, Ovarian Reserve, In Vitro Fertilization","enrollment":20},{"nctId":"NCT03423537","phase":"PHASE3","title":"Low-dose HCG as an Adjunct to Ovarian Stimulation in Subfertile Women Undergoing ART","status":"TERMINATED","sponsor":"National and Kapodistrian University of Athens","startDate":"2018-06-01","conditions":"HCG; IVF; Pregnancy Rates; ART; Chorionic Gonadotropin","enrollment":80},{"nctId":"NCT03447184","phase":"","title":"Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study","status":"COMPLETED","sponsor":"Mỹ Đức Hospital","startDate":"2018-03-26","conditions":"Poor Ovarian Response","enrollment":30},{"nctId":"NCT01816789","phase":"PHASE4","title":"Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles","status":"TERMINATED","sponsor":"Andros Day Surgery Clinic","startDate":"2013-03","conditions":"In Vitro Fertilization, Ovarian Stimulation","enrollment":194},{"nctId":"NCT01595334","phase":"NA","title":"Study on Influence of Leutinizing Hormone (LH) on Oocyte Maturity","status":"UNKNOWN","sponsor":"Southern Cross Fertility Centre","startDate":"2012-04","conditions":"Infertility","enrollment":300},{"nctId":"NCT01218386","phase":"PHASE4","title":"Pretreatment With Estradiol Valerate","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2010-05","conditions":"Infertility","enrollment":80},{"nctId":"NCT00374634","phase":"PHASE4","title":"Individual Versus Standard Follicle Stimulating Hormone Dose for Controlled Ovarian Stimulation and Insemination","status":"COMPLETED","sponsor":"Nina la Cour Freiesleben","startDate":"2006-09","conditions":"Infertility","enrollment":234}],"_emaApprovals":[],"_faersSignals":[{"count":448,"reaction":"OFF LABEL USE"},{"count":436,"reaction":"DRUG INEFFECTIVE"},{"count":390,"reaction":"PRODUCT QUALITY ISSUE"},{"count":378,"reaction":"NO ADVERSE EVENT"},{"count":288,"reaction":"DEATH"},{"count":281,"reaction":"NAUSEA"},{"count":266,"reaction":"DIARRHOEA"},{"count":253,"reaction":"FATIGUE"},{"count":244,"reaction":"DRUG DOSE OMISSION"},{"count":214,"reaction":"HAEMORRHAGE"}],"_approvalHistory":[{"date":"19870316","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"20250627","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"19850122","type":"ORIG","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"20181102","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"20170728","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"19930323","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"20000406","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"19920512","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"19920203","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"19880505","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"19940804","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"19920127","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"19860114","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"20210608","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"20070629","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"20000406","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"19930209","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"20041004","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"19960304","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"},{"date":"19870608","type":"SUPPL","sponsor":"DEPROCO","applicationNumber":"ANDA088390"}],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"\"Standard\" rFSH dose","genericName":"\"Standard\" rFSH dose","companyName":"Nina la Cour Freiesleben","companyId":"nina-la-cour-freiesleben","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant follicle-stimulating hormone (rFSH) stimulates the growth and maturation of ovarian follicles in women undergoing fertility treatment. Used for Infertility in women undergoing assisted reproductive technology (ART) / in vitro fertilization (IVF), Anovulation and ovulatory dysfunction.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}